What a fantastic finish! From launching the new 120-pulse Shockwave C2+ catheter in the U.S. to establishing a new Category I CPT® Add-on Code for coronary IVL, Q4 was filled with wave-making moments and positive momentum.
One highlight was the release of sex-specific outcomes data for both coronary and peripheral IVL from the DISRUPT PAD III, DISRUPT CAD III and CAD IV studies. Additionally, the DISRUPT PAD III study provided important data supporting the practice of sizing up by 10% for peripheral IVL. Look back at a few of our most noteworthy Q4 accomplishments and get excited about what’s coming in 2024 in the latest issue of the PulsePoint Newsletter.